1Foley J, Nickerson NK, Nam S, et al. EGFR signaling in breast cancer: Bad to the bone [J]. Semin Cell Dev Biol, 2010,21 (9) : 951-960.
2Li YW, Zhu GY, Shen XL, ct al. Furanodicnone induces celt cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells [ J ]. Cancer Che- mother Pharmacol, 2011,68 ( 5 ) : 1315-1323.
3Mill CP, Chester JA, Riese DJ. EGFR may couple moderate alcohol consumption to increased breast cancer risk [ J ]. Breast Cancer ( London), 2009,2009 ( 1 ) :31-38.
4Wilson KJ, Gilmore JL, Foley J, et al. Functional selectivity of EGF family peptide growth factors: implications for cancer [ J ]. Pharmacol Ther, 2009,122 (1) :1-8.
5Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine ki- nases [J]. Cell, 2010,141(7) :1117-1134.
6Willmarth NE, Baillo A, Dziubinski ML, et al. Altered EGFR lo- calization and degradation in human breast cancer ceils with an am- phiregulin/EGFR autocrine loop [ J ]. Cell Signal, 2009,21 ( 2 ) : 212-219.
7Gilmore JL, Gontcrman RM, Menon K, et al. Reconstitution of am- phiregulin-epidermal growth factor receptor signaling in lung squa- mous cell carcinomas activates PTHrP gene expression and contrib- utes to cancer-mediated diseases of the bone [ J]. Mol Cancer Res, 2009,7 (10) : 1714-1728.
8Yang XQ, Chen C, Peng CW, et al. Quantum dot-based quantita- tive immunofluorescence detection and spectrum analysis of epider- mal growth factor receptor in breast cancer tissue arrays [ J ]. Int J Nanomedicine, 2011,6:2265-2273.
9Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of the breast revisited : an old entity with new interpretations [ J ]. J Clin Pathol, 2008,61 (5) :553-560.
10Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promisingclinical target or only a marker [ J]. Cancer J, 2010, 16 ( 1 ) : 23 -32.
2Balslev I, Axelsson C K, Zedeler K, et al. The Notting- ham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) [J~, Breast Cancer Res Treat, 1994, 32 (3) :281-290.
3Burness M L, Grushko T A, Olopade O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a mark- er~J]. Cancer J, 2010, 16(1 ) :23-32.
4Park S, Koo J S, Kim M S, et al. Characteristics and outcomes according to molecular subtypes of breast canc- er as classified by a panel of four biomarkers using im- munobistochemistry [ J 1- Breast, 2012, 21 ( 1 ) :50-57.
5Gehrig P A, Van L L, Olatidoye B. Estrogen receptor status, determined by immunohistochemistry, as a pre- dictor of the recurrence of stage I endometrial carcinoma [ J]. Cancer, 1999, 86(10) :2083-2089.
6许良中,杨文涛.免疫组织化学结果的判定标准[J].中华癌症学杂志,2006,38(6):1-3.
7Cheang, M C, Chia S K, Voduc D,et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [ J]. J Natl Cancer Inst, 2009, 101 (10) :736-750.
8Nicholson R I. EGFR and cancer prognosis [ J]. Eur J Cancer, 2001, 37 (4) :9-15.
9Nielsen T O, Hsu F D, Jcnsen K,et al. Immunohisto- chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [ J ]. Clin Cancer Research, 2004, 10(16) :5367-5374.
10Kim M J, Ro J Y, Ahn S H,et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overex- pressing phenotypes [ J]. Human pathology, 2006, 37 (9) :1217-1226.
